Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) shares were down 8.1% during trading on Tuesday . The company traded as low as $0.86 and last traded at $0.91. Approximately 105,356 shares changed hands during mid-day trading, an increase of 615% from the average daily volume of 14,735 shares. The stock had previously closed at $0.99.
Eterna Therapeutics Price Performance
The stock has a market cap of $4.92 million, a PE ratio of -0.21 and a beta of 4.39. The business has a fifty day moving average of $1.39 and a 200 day moving average of $1.75.
Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.02) EPS for the quarter. The business had revenue of $0.05 million during the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%.
Institutional Inflows and Outflows
Eterna Therapeutics Company Profile
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Featured Stories
- Five stocks we like better than Eterna Therapeutics
- Investing in Construction Stocks
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Most Volatile Stocks, What Investors Need to Know
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.